All In MedTech

FDA Clearance Tracker · P250042

BAGUERA®C Cervical Disc Prosthesis

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Aug 10, 2026

Approved

Time to decision

283 days

Received Oct 31, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P250042
Device name
BAGUERA®C Cervical Disc Prosthesis
Applicant location
Laguna Hills, CA
Received
Oct 31, 2025
Decided
Aug 10, 2026
Decision
Approved
Supplements
2 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code MJO

FDA's approval statement

As written in FDA's record.

The BAGUERA® C Cervical Disc Prosthesis is indicated for use in skeletally mature patients for reconstruction of the disc at one or two contiguous levels from C3-C7 following single-level or two-contiguous-level discectomy for intractable radiculopathy (arm pain and/or a neurological deficit) with or without neck pain, or myelopathy due to a single-level or two-contiguous-level abnormality localized to the level of the disc space and manifested by at least one of the following conditions confirmed by radiographic imaging (e.g., X-rays, computed tomography (CT), magnetic resonance imaging (MRI)): herniated nucleus pulposus, spondylosis (defined by the presence of osteophytes), and/or visible loss of disc height as compared to adjacent levels. Patients receiving the BAGUERA® C Cervical Disc Prosthesis should have failed at least six weeks of non-operative treatment or have the presence of progressive symptoms (e.g., numbness or tingling) prior to implantation. The BAGUERA® C Cervical Disc Prosthesis is implanted via an open anterior approach.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code MJO. The earliest in FDA's data is P040006, decided Oct 26, 2004.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Spineart USA, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.